ST LOUIS (MD Consult) - On June 17, 2010, the US Food and Drug Administration (FDA) issued a notification concerning a fraudulent product being sold over the Internet claiming to be generic Tamiflu. Tests conducted by the FDA revealed that the product does not contain Tamiflu's active ingredient, oseltamivir, but does contain cloxacillin, an ingredient in the same class of antibiotics as penicillin. Patients who are allergic to penicillin products are at risk of experiencing similar reactions from exposure to cloxacillin.

No FDA-approved generic drug for the prescription product Tamiflu exists.

The FDA purchased the fraudulent "Generic Tamiflu" without a prescription from a Web site claiming to be an online drugstore (that is no longer operational). The FDA believes that the fraudulent version of Tamiflu is likely to be found for sale through other Web sites as well.

The FDA advises anyone possessing or encountering any of these fraudulent Tamiflu drugs to not use them and to contact the the agency's Office of Criminal Investigations.

圣路易斯(MD Consult)——2010年6月17日，美国食品药品管理局(FDA)就网上出售的声称为达菲仿制药的假冒药品发布了一则通告。FDA开展的试验结果显示，该产品不含有达菲的有效成分奥司他韦，但确实含有氯唑西林，后者为青霉素类抗生素中的一种成分。对青霉素药品过敏的患者服用氯唑西林有发生过敏反应的风险。

FDA至今尚未批准任何处方药达菲的仿制药。

FDA从声称作为网上药店的网站(已停止运作)在未提供处方的情况下购得此假冒的“达菲仿制药”。FDA认为通过其他网站可能也会找到假冒达菲出售。

FDA建议存有或遇到其中任何一种假冒达菲者切勿服用此药，同时联系FDA的犯罪调查办公室。